Ultragenyx Pharmaceutical
RARE
174 hedge funds and large institutions have $2.67B invested in Ultragenyx Pharmaceutical in 2020 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 68 increasing their positions, 48 reducing their positions, and 24 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 48
21% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 24
7% more capital invested
Capital invested by funds: $2.49B → $2.67B (+$185M)
3.11% more ownership
Funds ownership: 100.88% → 104% (+3.1%)
9% more call options, than puts
Call options by funds: $13.4M | Put options by funds: $12.3M
1% more funds holding
Funds holding: 173 → 174 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$54.2M |
| 2 |
Bank of New York Mellon
New York
|
+$24.6M |
| 3 |
Alkeon Capital Management
New York
|
+$12.5M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.3M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$23.2M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
-$13.3M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$12.5M |
| 4 |
BlackRock
New York
|
-$8.8M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$6.98M |
RARE Hedge Fund Activity: Q1 2020 in Review
174 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q1 2020, worth a combined $2.67B — up 7.4% from $2.49B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new RARE positions and 24 closed out — a net gain of 5 holders — while 68 added to existing stakes and 48 trimmed.
The largest buyer was Federated Hermes, adding an estimated $54.2M. The largest seller was Wellington Management Group, cutting an estimated $23.2M.
- 174 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q1 2020, up from 173 in Q4 2019.
- Funds reported $2.67B of Ultragenyx Pharmaceutical stock for Q1 2020, up 7.4% quarter-over-quarter.
- 29 funds opened new Ultragenyx Pharmaceutical positions in Q1 2020 and 24 closed out, a net change of +5 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q1 2020 was Federated Hermes, an estimated $54.2M added.
- The largest Ultragenyx Pharmaceutical seller in Q1 2020 was Wellington Management Group, an estimated $23.2M sold.
Based on aggregated 13F filings for Q1 2020.